Lunai Bioworks (LNAI)

• Market cap: $27.4M
• 1 day: -9.3%
• 5 days: -14.6%
• 1 month: 12.5%
• 3 months: -53.94%
• 6 months: -62.86%
• Year to date: -84.67%
• 1 year: -84.52%
• 5 years: -95.97%
• 10 years: -98.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Employees: 29